샘플 요청 목록

 카트 문의
시장보고서
상품코드
1857355

세계의 항우울제 시장

Antidepressants
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 174 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항우울제 시장은 2030년까지 176억 달러에 도달

2024년에 153억 달러로 추정되는 항우울제 세계 시장은 2024-2030년간 CAGR 2.5%로 성장하여 2030년에는 176억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 대우울증성 장애는 CAGR 2.2%를 나타내고, 분석 기간 종료시에는 70억 달러에 이를 것으로 예측됩니다. 강박성 장애 분야의 성장률은 분석 기간중 CAGR 1.6%로 추정됩니다.

미국 시장은 41억 달러로 추정, 중국은 CAGR 4.1%로 성장 예측

미국의 항우울제 시장은 2024년에 41억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 34억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 4.1%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.4%와 2.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.6%를 보일 것으로 예측됩니다.

세계의 항우울제 시장 - 주요 동향과 성장요인 정리

항우울제란 무엇인가?

항우울제는 주로 주요우울장애, 불안장애, 기타 기분 관련 증상의 치료에 사용되는 약물의 일종입니다. 이 약들은 신경세포 간의 소통을 담당하는 화학물질인 뇌 내 신경전달물질의 균형을 변화시킴으로써 작용합니다. 가장 일반적인 항우울제에는 선택적 세로토닌 재흡수 억제제(SSRI), 세로토닌 노르에피네프린 재흡수 억제제(SNRI), 삼환계 항우울제(TCA), 모노아민 산화효소 억제제(MAOI) 등이 있습니다. 플루옥세틴, 셀트랄린 등의 SSRI는 세로토닌의 뉴런으로의 재흡수를 억제하여 뇌 내 세로토닌 농도를 상승시켜 기분과 감정의 안정을 높입니다. 벤라팍신과 같은 SNRI도 마찬가지로 세로토닌과 노르에피네프린 수치를 증가시켜 SSRI에 반응하지 않는 환자에게 효과적인 이중 작용기전을 제공합니다. TCA와 MAOI는 효과적이지만 부작용의 범위가 넓기 때문에 일반적으로 심각한 경우에만 사용됩니다. 항우울제 선택은 환자별 증상, 이전 치료에 대한 반응, 잠재적 부작용에 따라 달라지며, 약물 관리에 대한 개별화된 접근이 필요합니다.

항우울제 치료의 최근 혁신은 무엇인가?

항우울제 치료 분야는 약리학의 발전과 우울증의 생물학적 기반에 대한 깊은 이해로 인해 최근 몇 년 동안 큰 혁신이 일어나고 있습니다. 가장 주목할 만한 발전 중 하나는 케타민과 그 유도체인 에스케타민과 같은 속효성 항우울제의 도입입니다. 이 약물들은 기존 항우울제가 효과가 나타나기까지 보통 몇 주에서 몇 달이 걸리는 것에 비해, 치료 저항성 우울증 환자에게 투여 후 몇 시간 내에 즉각적인 완화를 가져다 줄 것으로 기대되고 있습니다. 또한, 유전자가 약물에 대한 반응에 어떤 영향을 미치는지 연구하는 약리유전체학은 보다 개인화된 치료 접근법을 위한 길을 열어가고 있습니다. 환자의 유전자 프로파일을 분석함으로써 임상의는 어떤 항우울제가 가장 효과적이고 부작용이 적은지 예측할 수 있어 전반적인 치료 결과를 개선할 수 있습니다. 또한, 항우울제를 다른 약물요법이나 정신치료와 병용하는 병용요법도 개발되어 우울증 및 관련 질환의 관리를 위한 종합적인 접근을 제공합니다.

디지털 건강의 통합은 항우울제 사용에 어떤 영향을 미치고 있는가?

디지털 헬스 기술의 통합은 항우울제 치료의 제공 및 모니터링 방식에 혁명을 일으키고 있습니다. 원격 의료 플랫폼을 통해 환자들은 집에서도 의료진과 상담할 수 있으며, 특히 의료 서비스가 부족한 지역에서 정신 건강 서비스에 대한 접근성이 향상되고 있습니다. 디지털 건강 앱과 웨어러블 기기 역시 환자의 정신 건강 상태와 복약 순응도를 모니터링하는 데 중요한 역할을 하고 있습니다. 이러한 도구는 기분 변화, 수면 패턴, 활동 수준을 추적할 수 있으며, 임상의가 치료 계획을 보다 효과적으로 조정하는 데 사용할 수 있는 실시간 데이터를 제공합니다. 또한, 질병을 예방, 관리, 치료하기 위해 고안된 소프트웨어 기반 개입 방법인 디지털 치료는 기존의 항우울제 치료를 보완하는 도구로 부상하고 있습니다. 예를 들어, 인지행동치료(CBT) 앱은 환자가 약물 치료와 병행하여 대처전략을 익히고 정신건강을 개선할 수 있도록 안내된 치료 세션을 제공할 수 있습니다. 이러한 디지털 솔루션의 편의성과 접근성을 통해 환자들은 치료 계획을 더 쉽게 지킬 수 있고, 궁극적으로 치료 결과를 개선하고 항우울제의 전반적인 효과를 높일 수 있습니다.

항우울제 시장의 성장을 가속하는 요인은 무엇인가?

항우울제 시장의 성장은 기술 발전, 치료 패러다임의 진화, 소비자 행동의 변화 등 여러 가지 요인으로 인해 발생합니다. 빠른 효과를 보이는 항우울제 개발 및 약리유전체학 통합과 같은 기술 혁신은 치료의 선택권을 넓히고 환자 결과를 개선하고 있습니다. 우울증과 불안장애의 유병률 증가는 코로나19 팬데믹과 같은 전 세계적인 스트레스 요인으로 인해 더욱 악화되고 있으며, 효과적인 항우울제 치료에 대한 수요가 크게 증가하고 있습니다. 또한, 정신건강 문제에 대한 인식과 수용도가 높아지면서 편견이 사라지고 더 많은 사람들이 치료를 받을 수 있게 되었습니다. 원격 의료와 디지털 헬스 플랫폼의 등장은 정신 건강 서비스에 대한 접근성을 확대하고, 환자들이 처방과 후속 치료를 쉽게 받을 수 있도록 돕고 있습니다. 새로운 항우울제 치료에 대한 규제적 지원은 정신 건강 연구 및 개발에 대한 활발한 투자와 함께 기술 혁신을 촉진하고 새로운 치료법을 시장에 출시할 수 있도록 돕습니다. 또한, 환자 개개인프로파일에 맞추어 치료가 이루어지는 개인 맞춤형 의료의 추세는 항우울제 치료의 효과를 높이고 있습니다. 그 결과, 기술 발전, 수요 증가, 의료 서비스 제공 모델의 진화가 겹치면서 시장은 지속적으로 성장하고 있습니다.

부문

장애(주요 우울 장애, 강박 장애, 일반화 불안 장애, 공황 장애, 기타 장애); 제품(삼환계 항우울제, 선택적 세로토닌 재흡수 억제제, 세로토닌-노르에피네프린 재흡수 억제제, 모노아민 산화효소 억제제, 세로토닌 길항제 및 재흡수 억제제, 기타 제품)

조사 대상 기업 예

  • Allergan PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck & Co., Inc.
  • Otsuka America Pharmaceutical, Inc.
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.11.10

Global Antidepressants Market to Reach US$17.6 Billion by 2030

The global market for Antidepressants estimated at US$15.3 Billion in the year 2024, is expected to reach US$17.6 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Major Depressive Disorder, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Obsessive-Compulsive Disorder segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.1 Billion While China is Forecast to Grow at 4.1% CAGR

The Antidepressants market in the U.S. is estimated at US$4.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Antidepressants Market - Key Trends and Drivers Summarized

What Are Antidepressants and How Do They Work?

Antidepressants are a class of medications primarily used to treat major depressive disorder, anxiety disorders, and other mood-related conditions. These medications function by altering the balance of neurotransmitters in the brain, which are chemicals responsible for communication between nerve cells. The most common types of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). SSRIs, such as fluoxetine and sertraline, increase the levels of serotonin in the brain by inhibiting its reabsorption into neurons, thereby enhancing mood and emotional stability. SNRIs, like venlafaxine, similarly boost levels of serotonin and norepinephrine, providing a dual mechanism of action that can be effective for patients unresponsive to SSRIs. TCAs and MAOIs, while effective, are typically reserved for more severe cases due to their broader range of side effects. The choice of antidepressant depends on the patient's specific symptoms, response to previous treatments, and potential side effects, necessitating a personalized approach to medication management.

What Are the Recent Innovations in Antidepressant Therapy?

The field of antidepressant therapy has seen significant innovations in recent years, driven by advances in pharmacology and a deeper understanding of the biological underpinnings of depression. One of the most notable developments is the introduction of rapid-acting antidepressants, such as ketamine and its derivative esketamine. These drugs have shown promise in providing quick relief for patients with treatment-resistant depression, often within hours of administration, compared to the weeks or months typically required for traditional antidepressants to take effect. Additionally, pharmacogenomics, the study of how genes affect a person's response to drugs, is paving the way for more personalized treatment approaches. By analyzing a patient's genetic profile, clinicians can predict which antidepressants are likely to be most effective and have the fewest side effects, improving overall treatment outcomes. The development of combination therapies, where antidepressants are used in conjunction with other medications or psychotherapeutic interventions, is also gaining traction, offering a more holistic approach to managing depression and related disorders.

How Is the Integration of Digital Health Influencing Antidepressant Use?

The integration of digital health technologies is revolutionizing the way antidepressant treatments are delivered and monitored. Telemedicine platforms enable patients to consult with healthcare providers from the comfort of their homes, increasing access to mental health services, particularly in underserved areas. Digital health apps and wearable devices are also playing a crucial role in monitoring patients' mental health status and medication adherence. These tools can track mood changes, sleep patterns, and activity levels, providing real-time data that clinicians can use to adjust treatment plans more effectively. Additionally, digital therapeutics, which are software-based interventions designed to prevent, manage, or treat medical conditions, are emerging as complementary tools to traditional antidepressant therapy. For example, cognitive-behavioral therapy (CBT) apps can provide guided therapy sessions, helping patients develop coping strategies and improve their mental health alongside medication. The convenience and accessibility of these digital solutions are making it easier for patients to stick to their treatment plans, ultimately improving outcomes and enhancing the overall effectiveness of antidepressant therapies.

What Drives the Growth in the Antidepressant Market?

The growth in the antidepressant market is driven by several factors that span technological advancements, evolving treatment paradigms, and changing consumer behaviors. Technological innovations, such as the development of rapid-acting antidepressants and the integration of pharmacogenomics, are expanding treatment options and improving patient outcomes. The increasing prevalence of depression and anxiety disorders, exacerbated by global stressors such as the COVID-19 pandemic, generates significant demand for effective antidepressant therapies. There is also a growing acceptance and awareness of mental health issues, reducing stigma and encouraging more individuals to seek treatment. The rise of telemedicine and digital health platforms is expanding access to mental health services, making it easier for patients to obtain prescriptions and follow-up care. Regulatory support for new antidepressant therapies, coupled with robust investment in mental health research and development, is fostering innovation and bringing new treatments to market. Furthermore, the trend towards personalized medicine, where treatments are tailored to individual patient profiles, is enhancing the efficacy of antidepressant therapies. As a result, the market is seeing sustained growth, driven by a confluence of technological advancements, increased demand, and evolving healthcare delivery models.

SCOPE OF STUDY:

The report analyzes the Antidepressants market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Other Disorders); Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, Other Products)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Allergan PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck & Co., Inc.
  • Otsuka America Pharmaceutical, Inc.
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Antidepressants - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Depression and Anxiety Disorders Generates Demand for Antidepressants
    • Innovations in Pharmacogenomics Expand Addressable Market Opportunity
    • Growing Acceptance and Awareness of Mental Health Issues Strengthen Business Case for Antidepressants
    • Development of Novel Antidepressant Classes Spurs Market Growth
    • The Shift Towards Personalized Medicine Throws the Spotlight on Tailored Treatment Options
    • Rise in Telemedicine and Digital Health Platforms Expands Access to Antidepressants
    • Integration of Antidepressants with Psychotherapy and Counseling Services Generates Holistic Treatment Opportunities
    • Trends in Rapid-Acting Antidepressants Accelerate Demand for Immediate Relief Options
    • Increasing Use of Antidepressants in Pediatric and Geriatric Populations Sustains Market Expansion
    • Emergence of Combination Therapies Strengthens Business Case for Multi-Modal Treatments
    • Consumer Preference for Non-Pharmacological Treatments Creates Opportunities and Challenges
    • The Role of Antidepressants in Treating Comorbid Conditions Expands Market Potential
    • Trends in Generic Antidepressants and Biosimilars Impact Market Dynamics and Pricing
    • Technological Advancements in Drug Delivery Systems Propel Growth in Antidepressant Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antidepressants Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Major Depressive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Major Depressive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Major Depressive Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Obsessive-Compulsive Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Obsessive-Compulsive Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Generalized Anxiety Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Generalized Anxiety Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Generalized Anxiety Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Panic Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Panic Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Panic Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Tricyclic Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Tricyclic Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Selective Serotonin Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Monoamine Oxidase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Monoamine Oxidase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Monoamine Oxidase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Serotonin Antagonist & Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Serotonin Antagonist & Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Serotonin Antagonist & Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • JAPAN
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • CHINA
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • EUROPE
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Antidepressants by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • FRANCE
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • GERMANY
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Spain 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Russia 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Antidepressants by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Australia 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • INDIA
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: India 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: South Korea 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Antidepressants by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Argentina 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Brazil 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Mexico 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Antidepressants by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Iran 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Israel 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: UAE 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030
  • AFRICA
    • Antidepressants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Antidepressants by Disorder - Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Africa 15-Year Perspective for Antidepressants by Disorder - Percentage Breakdown of Value Sales for Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Other Disorders for the Years 2015, 2025 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Antidepressants by Product - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for Antidepressants by Product - Percentage Breakdown of Value Sales for Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors and Other Products for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제